

---

## **Summary of risk management plan for Melatonin Aspire (hereafter referred to as Melatonin oral solution):**

This is a summary of the risk management plan (RMP) for Melatonin oral solution. The RMP details important risks of Melatonin oral solution, how these risks can be minimised, and how more information will be obtained about Melatonin oral solution's risks and uncertainties (missing information).

Melatonin oral solution's summary of product characteristics (SmPC) and package leaflet (PL) give essential information to healthcare professionals and patients on how Melatonin oral solution should be used.

### **I. The medicine and what it is used for**

In SE, DK, DE, NL, NO, FI, Melatonin oral solution is authorised for:

- Short-term treatment of jet-lag in adults.
- Sleep onset insomnia in children and adolescents aged 6-17 years with attention deficit hyperactivity disorder (ADHD), where sleep hygiene measures have been insufficient.

Melatonin oral solution contains melatonin as the active substance, and it is given by oral route.

### **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of Melatonin oral solution, together with measures to minimise such risks and the proposed studies for learning more about Melatonin oral solution's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the PL and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size- the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status- the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation measures*.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including periodic safety update report (PSUR) assessment, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

#### **II.A List of important risks and missing information**

Important risks of Melatonin oral solution are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Melatonin oral solution. Potential risks are concerns for which

an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

<b>List of important risks and missing information</b>	
<b>Important identified risk</b>	None
<b>Important potential risk</b>	None
<b>Missing information</b>	None

## **II.B Summary of important risks**

There are no important risks or missing information associated with Melatonin Oral Solution.

## **II.C Post-authorisation development plan**

### ***II.C.1 Studies which are conditions of the marketing authorisation***

There are no studies which are conditions of the marketing authorisation or specific obligation of Melatonin Oral Solution.

### ***II.C.2 Other studies in post-authorisation development plan***

There are no studies required for Melatonin Oral Solution.